Codiak BioSciences IPO

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register for Details

For more details on financing and valuation for Codiak BioSciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Codiak BioSciences's ticker symbol?

CDAK

What is Codiak BioSciences's stock price?

0.19 as of 3/28/23

Codiak BioSciences Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
11/29/2017 Series C $404.14MM $XXX.XX $XXX.XX
1/26/2016 Series B $296MM $XXX.XX $XXX.XX
11/25/2015 Series A $76.5MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Codiak BioSciences

Forge green plus iconForge green minus icon

What is Codiak BioSciences funding to date?

Codiak BioSciences has raised $168.37MM with the following series:
$76.5MM for Series A, $296MM for Series B, $404.14MM for Series C, $76.5MM for Series A, $296MM for Series B, $404.14MM for Series C.
Forge green plus iconForge green minus icon

When was Codiak BioSciences founded?

Codiak BioSciences was founded in 2015.